Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

43.35B

Market cap43.35B

Price-Earnings ratio

136.79

Price-Earnings ratio136.79

Dividend yield

—

Dividend yield—

Average volume

1.07M

Average volume1.07M

High today

$330.50

High today$330.50

Low today

$317.25

Low today$317.25

Open price

$319.20

Open price$319.20

Volume

913.55K

Volume913.55K

52 Week high

$495.55

52 Week high$495.55

52 Week low

$205.87

52 Week low$205.87

Stock Snapshot

The current Alnylam Pharmaceuticals(ALNY) stock price is $330.15, with a market capitalization of 43.35B. The stock trades at a price-to-earnings (P/E) ratio of 136.79.

On 2026-03-04, Alnylam Pharmaceuticals(ALNY) stock moved within a range of $317.25 to $330.50. With shares now at $330.15, the stock is trading +4.1% above its intraday low and -0.1% below the session's peak.

Trading activity shows a volume of 913.55K, compared to an average daily volume of 1.07M.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

ALNY News

Simply Wall St 1d

The Bull Case For Alnylam Pharmaceuticals Could Change Following AMVUTTRA Uptake And Canada Reimbursement News

In late February 2026, Alnylam Pharmaceuticals highlighted strong momentum for its RNAi franchise, including positive Phase 3 data and a favorable Canadian reim...

TipRanks 2d

Alnylam’s KARDIA-3 Hypertension Trial Reaches Completion, Raising Key Questions for ALNY Investors

Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study. KARDIA-3 tests Alnylam’s drug zilebesiran as add-on therapy for adults with...

Simply Wall St 4d

Alnylam Phase 1 ALN-4285 Data Highlights Expanding RNAi Platform Potential

Alnylam Pharmaceuticals (NasdaqGS:ALNY) reported a new update on its Phase 1 clinical study of ALN-4285. The RNA based drug targets a novel disease related pro...

Analyst ratings

77%

of 30 ratings

Buy

76.7%

Hold

23.3%

Sell

More ALNY News

TipRanks 5d

Alnylam’s New Phase 1 ALN-4285 Trial: What Early Safety Data Could Mean for ALNY Investors

Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study. Alnylam Advances New RNA Drug With Early Safety Study in Healthy Adults. Al...

Simply Wall St 6d

A Look At Alnylam Pharmaceuticals Valuation After Recent Share Price Pullback

Alnylam Pharmaceuticals (ALNY) has been drawing interest after recent trading, with the share price around $331.24 and mixed short term returns, including a 7 d...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Eli Lilly

Vertex Pharmaceuticals

Broadcom

Netflix

Taiwan Semiconductor Manu…

AMD

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.